skip to content

Early Cancer Institute


Project DELTA aim

Our vision is to redesign the clinical pathway for reflux. A new algorithm applied to NHS prescribing databases will flag symptomatic individuals at risk for oesophageal cancer to their GP. Individuals at risk will be offered a Cytosponge test in a nurse led clinic. The TFF3 stained cells collected by the Cytosponge will be assessed using Artificial Intelligence to increase the throughput and reduce the cost. Individuals at high risk for cancer will be referred for endoscopy and PPI use will be rationalised. These changes will result in an economic benefit to the NHS, a social benefit for early detection of a lethal cancer and a reduction in over-use of PPI medication.

Project DELTA website